What is a dual GIP/GLP-1 receptor co-agonist?
A dual GIP/GLP-1 receptor co-agonist is a medicine that activates both the GIP and GLP-1 receptors in the body, which are involved in controlling blood sugar and appetite. Mounjaro (tirzepatide) is the main example of this type of drug and is used for weight loss as well as diabetes. By targeting both receptors, Mounjaro can help people lose more weight than medicines that only target GLP-1.
- Dual GIP/GLP-1 co-agonists work by activating two hormone pathways that help regulate appetite and blood sugar.
- Mounjaro (tirzepatide) is the first approved medicine of this type and is used for weight loss and diabetes.
- Mounjaro has shown greater weight loss than older GLP-1-only medicines in studies.
- This medicine is given as a weekly injection.
- By working on both receptors, it may reduce side effects seen with GLP-1-only drugs and improve effectiveness.
This text has been fact checked for accuaracy by Sorin Romaniuc, Pharmacist at medino.